View Article

Abstract

Comprehensive review deals with the intranasal drug delivery from nose to brain for managing Alzheimer’s disease. Notably, intranasal drug delivery has shown neuroprotective effects like A?-amyloid protein, tau protein and synaptic plaques. In preclinical studies and clinical trials intranasal drug delivery has shown rapid and extensive distribution throughout the brain. Mechanism of nose to brain drug delivery with its pathophysiology has been shown in this review. It shows the detailed emphasises review on nanoparticles used for drug delivery and the liposomes as a carrier for the Alzheimer’s disease, it also deals with the various challenges and the needs for the drug delivery. Liposomal drug delivery systems offer several advantages over traditional methods for delivering drugs and nucleic acids from the nose to the brain Many in vivo and invitro models are being studied in the review.

Keywords

Intranasal drug delivery, Nose-to-brain, Alzheimer's disease, A?-amyloid reduction, Tau protein targeting

Introduction

A] Introduction        

Alzheimer's malady, the most predominant cause of dementia, is still characterized by the combined nearness of amyloid and tau, but analysts are slowly moving absent from the straightforward suspicion of straight causality as proposed in the unique amyloid theory. Age-related, defensive, and disease-promoting variables likely connected with the centre instruments of the malady (1). Dementia is the fifth driving cause of passing all inclusive (2) and Advertisement the fourth driving cause of disability-adjusted life-years (DALYs) misplaced in people matured 75 a long time and more seasoned (3). In expansion, most patients have one or more family caregivers who commit time and exertion in unpaid care, coming about in mental dismalness, social segregation, physical sick wellbeing, and money related hardship. We see two critical confinements to this narrative (4). AD is the essential cause of feebleness in swarm over the age of 60. Around 50–75% of individuals going with feebleness have Alzheimer’s. As per the scientific file calm common, females are more subordinate on something Advertisement than men, and the chance increments indeed taking after age. Individuals going with cardiovascular sufferings, hypertension, and diabetes are too at greater chance of bearing Advertisement afterward. This no question is the prevalent cause of raised Advertisement cases in immature nations, owing to population’s behaviour. Patients going with impartial appearances comparative to Alzheimer’s but not appearance a few pathophysiology had association with the torment, perhaps the things who are stressed approximately self-evident steady failure to keep in mind indeed when talented is no encapsulation for impedance. This condition is well known as ‘anxious well’, the possessions of inebriating and drugs, and individuals as political entirety going with emotional ailments appear previously mentioned appearances. Other neurodegenerative disarranges going with Advertisement like signs contain frontotemporal dementia and Lewy outline feebleness; instigative, metabolic and catching condition; vascular shrewdly impedance; and a progression of causes that include restricting rest apnoea and brief epileptic memory misfortune  (5).

B] Overview of Alzheimer’s disease

We erect that despair and brilliant degradation were the first syndromes to act in 98.5% and 99.1% of belongings in a study following late-attack AD (LOAD) and 9% and 80%, separately, in early-attack AD (EOAD). Memory required gave early and was knowledgeable 12 age before the clinically demarcated AD dotage in the LOAD. However, the fast growing late-attack AD allotted primarily following 35 non-settled concern a focus syndromes and signs holding myoclonus (75%), disorganized walks (66%) and severity. These were misdiagnosed as syndromes of Creutzfeldt-Jacob illness (CJD) efficiently the cases. The wife accompanying antagonistic miniature-mindset test score of 25 waited available 2 age, that is to say agreeable accompanying current situation of the wholesome child limbs (6).The verdicts concerning this study support the well proved high predominance of BPSD in cases accompanying AD. Our study erects that most types of BPSD were not guide ailment severity except that delusion. This judgment increases an increasing literature on BPSD in sufferers accompanying AD. Interestingly, the study revealed that shaking was the only syndrome that was powerfully associated with two together caretaker burden and despair (7).

Symptoms of Alzheimer’s disease include:

The first syndromes are frequently mistakenly from developing or stress. Detailed neuropsychological testing can disclose gentle cognitive troubles until eight ages before a person conforms the dispassionate criteria for disease of Alzheimer's disease. These early syndromes can affect ultimate complex exercises of regularly living. The most noticeable required is temporary memory deficit, that shows up as trouble in remembering currently well-informed facts and failure to achieve new information. Subtle questions accompanying the executive functions of consideration, planning, elasticity, and abstract thinking, or degradations in pertaining to syntax thought (thought of meanings, and idea connections) can likewise signify of the beginning of Alzheimer's disease. Apathy and cavity can be visualized at this stage, accompanying indifference staying as ultimate persistent manifestation during the whole of the course of the affliction. Mild (MCI) is frequently erect to be an erratic stage 'tween common fermenting and senility. MCI can present accompanying a variety of manifestations, and when thought deficit is the ruling manifestation, it is termed forgetful MCI and is repeatedly visualized as a above stage of Alzheimer's disease. Amnesic MCI has a more 90% likelihood of being guide (8).

The Stages of Alzheimer’s Disease

The clinical phases of Alzheimer’s disease can be classified into: -

  • Pre-dispassionate or the pre-indicative stage, that can last for various age or more. This stage is characterized by temperate thought deficit and early unhealthy changes in bark and hippocampus, accompanying no working degradation in the often actions and absence of dispassionate signs and manifestations of AD.
  • The gentle or beginning of AD, place various syndromes start to perform in inmates, such as a trouble in the regular history of the patient accompanying a deficit of aggregation and thought, puzzlement of place and opportunity, a change ready, and a growth of despair.
  • Moderate AD stage, at which point the affliction spreads to cerebral layer districts that results in a raised thought loss scarcely understanding offspring and friends, a misfortune of drive control, and trouble in knowledge, writing, and talking. Severe AD or late-stage, that includes the spread of the disease to the complete bark area accompanying a harsh growth of neurotic plaques and neurofibrillary tangles, developing in a growing functional and intelligent deterioration place the patients cannot understand; their offspring at all and can enhance ill with troubles in taking into throat and urination, and someday superior to the patient’s demise due to these confusions (8).
  1. Risk Factors of Alzheimer’s Disease
  • Redefining Alzheimer's Disease: -

For decades, AD has happened outlined as a clinical-healing assemble called “likely or feasible AD” and has been habitual all the while autopsies apiece closeness of Neuritic plaques and neurofibrillary tangles. As a consequence, the term AD has been used to specify two together the neuropathological entity in addition to the typical clinical disease of thought loss and different intelligent problems. Over the following quarter-centennial, questions at this moment conceptualization arose (9).           

Fig1.The risk factors for Alzheimer’s disease (8)

  1. Distinguishing AD dementia from other major forms of dementia

Alzheimer’s ailment (AD) is a deteriorating brain affliction that frequently starts in late life and results in a liberal senility. AD is distinguished pathologically by neuronal atrophy, synapse deficit and the uncommon aggregation of amyloid-β protein (Aβ) as senile plaques and hyperphosphorylated tau protein as neurofibrillary tangles. In most cases, neurofibrillary tangles originally include middle temporal flap forms (for instance, hippocampus and entorhinal cortex) and therefore stretch to worldly, parietal and frontal flap partnership districts as the disease progresses, while Aβ dethroning starts in parietal, momentary and frontal partnership districts. Primary neurological and motor cortices and most subcortical forms are approximately forgiven until late in the affliction process. Degeneration in basic forebrain makeups results in a major decline of cortical, limbic and hippocampal cholinergic projections. The usual senility syndrome of AD is from important intermittent memory deterioration, accompanying subordinate deficits in discussion-verdict abilities, spatial understanding and executive functions (10).

  1. The role of the immune system in Alzheimer’s disease

These are myeloid containers (like microglia) and form unspecified the first line of defence against contamination by microorganisms in the way that microorganisms, viruses and fungi. Cells of the inherited invulnerable arrangement have a collection of beginning-line encrypted pattern-recognition receptors (PRRs) that recognise the conserved microscopic patterns on penetrating structures famous as pattern-befriended microscopic patterns (PAMPs). In addition, the PRRs sense hazard-joined microscopic patterns (DAMPs), that are announced all along occurrence of clean redness in the way that machinelike confusion or blood deficiency. PRRs are widely detached into four categories, Toll-like receptors (TLR), Nucleotide-binding oligomerization rule-like receptors (NLR), C-type lectin receptors (CLR) and RIG-1 like receptors (RLR) (11).

C] Pathophysiology of Alzheimer’s type dementia: -

There are a lot of neurons in the intelligence, each holding an axon and various dendrites. Neurons demand ideas, absorption, and self-repair in consideration of be healthful. All three of these important tasks are upset by AD. Neuritic plaques/ β-amyloid plaques and neurofibrillary tangles (NFTs) are two of AD's different lesions. Firstly, in the case of Neuritic plaques, deposits of the β-amyloid protein fragment amplify in the breach middle from two points nerve containers (neurons). The component of amyloid memorial is the amyloid forerunner protein (APP) that sticks through the neuron sheet, and enzymes like β-secretase and α-secretase cut the APP into fragments of protein (neurotoxic Aβ42 fragments), containing β-amyloid. Thus β-amyloid fragments meet in clumps to form plaques. Numerous of these aggregates evolve in AD, obstruct the function of neurons. This for the most part impacts the hippocampus and different parts of the using one's brain layer. Secondly, in the case of NFTs, microtubules compensate any of the within support makeup of neurons. Microtubules are helped in their cohesion by a protein famous as tau. When “tau” is changed in AD, the microtubules decay, and the tau protein collects to form neurofibrillary tangles (Tsering and Prokop, 2023). However, further all along AD, neurons from few regions of the mind, exceptionally the rind and limbic domain, containing the hippocampus and amygdala, evenly shame and eventually bring about the obliteration of the neurons, on account of that the intelligence is stated expected tinier in breadth, folds and grooves of external coatings are dwindle, and ventricles are best distinguished to an active mind (13).

Fig2. Main differences between a healthy brain and a brain with Alzheimer-type dementias (14)

D] Therapeutic approaches for stem cell therapy

Stem cell therapy: -

Stem vessel drug has been noted anticipated a disease- lessening situation for Alzheimer’s disease(announcement). After the collapse to develop new medicines for announcement, the number of studies on stem holders, in the way that mesenchymal stem holders(MSCs) and affecting amp   whim-whams organs stem holders( NSCs), has raised from the early 2000 s. Issues pertaining to stem holders have  happed examined in  numerous beast studies in conditions of stem  vessel  commencement, isolation effectiveness, pattern of education, tumour composition, cure route, and mobility. Since 2010, primarily in East Asia, judges started equitable tests fact- chancing the use of stem cells for announcement. Two state I tests on moderate announcement have been achieved; though they told no harsh acute or general responses, no important equitable effectiveness was noticed. Several studies, which include more advanced study designs exercising  colourful needle routes, well- established scales, and biomarkers in the way that amyloid positron  allocation tomography, are believe gentle to moderate announcement subjects. Then, we review the idea of stem cell remedy for announcement and the progress of current  equitable tests (15).

E] Mechanism of intranasal drug delivery to the brain: -

In this review, the carnal pathways and makeups had connection with medicine transfer from the nasal crater to the mind are presented by separating bureaucracy into natural and lymphoid types. Figure shows a diagrammatic delineation of the physiologic schemes complicated in nasal- mind medicine transfer. The direct routes of medicine parturition from the nasal crater (inky spotted arrows in Fig. A, B, and D) to the intelligence and cloverleaf routes (sky spotted arrows in Fig. B – D) through the abecedarian distribution were described. Brain targeting through the intranasal route  generally occurs through three pathways the respiratory pathway( a  circular route), the olfactory pathway, and the trigeminal pathway( a direct route) (16).Intranasally administered  medicines can travel through different pathways, including  immersion by the nasal mucosa into the systemic rotation, axonal transport to the olfactory bulb, or direct entry through the trigeminal  whim-whams (17). Both the olfactory and trigeminal pathways are considered effective and safe routes for delivering active substances to the brain (18).Gaining a comprehensive understanding of the mechanisms underpinning these pathways is essential for  contriving effective  remedial strategies for Alzheimer’s  complaint. The olfactory neuronal pathway encompasses intra- and extra-neuronal mechanism (19), gauging  the olfactory epithelium, olfactory bulb, and lamella propria. Administered medicines reach the olfactory bulb from the olfactory region through a transcellular medium. also,  colourful mechanisms  similar as paracellular transport, transcytosis, and  prolixity, as well as the involvement of efflux transporters (20), can come into play grounded on the physicochemical  parcels of the  medicine. The olfactory bulb serves as a direct conduit for distributing the  medicine to different brain regions, including the piriform cortex, hypothalamus, and Amygdala(21).

Fig 3. Schematic drawing of the physical orders involved in drug childbirth from the nasal crater to the intellect. The having fragrance road (A), the respiring pathway (B), the integral road through the BBB (C), and NALT (D) are bestowed as attainable pathways for nasal-intellect drug transfer. BBB and NALT are blood–brain-impediment and nasopharynx-mixed lymphoid fabric, individually. In A, a–c shows transcellular (through olfactory epithelial containers), paracellular (through affecting animate nerve organs epithelial containers), and affecting animate nerve organs nerve pathways, individually. The angry dotted arrows in A, B, and D display direct drug transmittal routes from the nasal crater to the intelligence. The blue spotted arrows in B–D indicate unintended drug transfer pathways from the nasal crater to the mind (22).

F] Nano particles for nose to brain delivery: -

In nanoparticle-located arrangements have been explained to raise the permeability and assimilation of drugs, their uptake in the affecting animate nerve organs domain, and their approach and accumulation into the CNS. At the same time, they can defend healing powers from degradation and forbid their extracellular transport by extroverted transporters. Moreover, the blend of nanotechnology with additional game plans has granted to favour the accumulation of IN nanoparticulate-located wholes into the CNS. Several surfactants are used to simplify drug permeation, to a degree pegylated fragments, while mucoadhesive polymers intelligent to interact accompanying mucin, to a degree chitosan, are used to extend its palace opportunity. On the other hand, combining cell-stinging peptides (CPP) that can communicate accompanying biological membranes advances natural rude answer. The use of nanoparticulate-based arrangements together with added plannings in the way that incorporating transportation enhancers and/or mucoadhesive powers, with others, has authorized to gain a taller degree of discriminating drug transfer to the mind. Different nanoparticulate-based structures have proved hopeful in vivo results related to pharmacokinetic limits in the mind later an IN administration. Important mind pharmacokinetic limits were reinforced, increasing Cmax (maximum drug aggregation in the goal fabric), area under the curve (AUC, matching to the complete of the body tissue concentration —or fabric aggregation— of a drug against an outlined time pause), and mean memory opportunity, while reducing Tmax (period wanted to gain the Cmax in the target side (23). Although progress has been positive, there are still persistent limitations and challenges that must be addressed to achieve consistent and predictable nose-to-brain drug delivery. First of all, the intranasal administration dosage is really limited, with young men and women having a nose volume of about 6 cm3, and can only be administered under 200 μl. Moreover, the rapid clearance of drugs from the nasal cavity and the potential for enzymatic degradation present hurdles that require further investigation. Also, the nasal mucus, nasal epithelium, and lamina propria collectively form the inherent anatomical barrier to the nose-to-brain drug delivery. Last but not least, the possible toxicity on nasal cilia or different nasal cells, the generation of local inflammation, and the potential systemic effect are the primary safety concerns (24).         

Fig4. Different explored strategies to ameliorate the nose-to-brain drug delivery using polymer NP (23).

G] Amyloid Beta Precursor Protein Processing:

In AD subjects, the digesting of APP is finished by accruing operation of beginning- and gamma-secretases that produce mysterious peptides, amyloid-testing, that cluster together to form amyloid suspect plaques accordingly decaying containers (25). In active minds, gap of Aβ is finished by being tested-secretase enzymes happening in the establishment of dissolved APP fragments, and so forth of the APP is further cleaved by γ-secretase-bearing peptides that are freed outside the container and expeditiously detached/disgraced. However, in old family, the secretase equilibrium is dysregulated, and APP is cleaved by β and γ-secretase and produces mysterious amyloid being tested peptides. APP deoxyribonucleic acid in persons is situated on deoxyribonucleic acid 21 and alternate splicing concerning this deoxyribonucleic acid produces 8–11 isoforms of APP protein of various amino acid lengths. APP is a transmembrane protein namely moved through secretory and endocytic pathways. Among allure isoforms, APP 751 and APP 770 are raise expected articulated in glial containers, and supply support for neurons, and APP 695 is articulated in neurons (26).APP proteolysis in persons understands amyloidogenic and non-amyloidogenic pathways (in figure likely). The amyloidogenic road involves the handle of APP apiece operation of β- and γ-secretases. β-Secretase (BACE-1) cuts APP into the sheath-bound fragment popular as C-terminal fragment β (CTFβ) and N-terminal dissolved APPβ (sAPPβ) (27). CTFβ is further cleaved by γ-secretases and create extracellular Aβ protein fragments and APP intracellular rule (AICD) (28).  The non-amyloidogenic pathways process APP for one operation of sheet-limited something which incites activity α-secretase that cuts inside the Aβ series and produce sheath-bound C-terminal fragment CTFα and N-terminal fragment sAPPα. Further deal with of CTFα yields extracellular P3 fragments and APP intracellular rule (AICD) (27).

Figure 5. Amyloid forerunner protein (APP) converts. Two proteolytic pathways, amyloidogenic and non-amyloidogenic handle, live for APP convert. The amyloidogenic road includes β and γ secretases and releases N-terminal dissolved APPβ fragments, and Aβ peptides in the extracellular domain. The non-amyloidogenic includes α and γ secretases and releases N-terminal APPα fragments, and P3 peptides in the extracellular domain. Both proteolytic pathways release APP intracellular rule (AICD) fragments intracellularly (29)

H] Liposomes as carrier for drug delivery in Alzheimer's disease

The swift change progress of nanotechnology has appealed to on healing businesses, exceptionally for wit disorders. Over past events few age, interest in liposomes as alternative labour schemes for pharmaceuticals has nurtured indirect their extraordinary changeability, biocompatibility, and capability to stop drug deterioration and lower inadmissible personal possessions. More recently, they have lived second argue for intellect determine, deoxyribonucleic acid reasoning, and tumour position, liposomal game plans for AD position. Intervening liposomes as ships that bear airplanes for the remedy of AD displays neighbourhood-individuality and many more benefits than low portion of drug or additional usable forms. The use of peptides that pierces the mind, in addition to ligands mean Aβ, hindering that phosphatidic acid, curcumin, and a from time elapsed-inverted peptide, all have lied used to lower liposomes before this time that confine Aβ accumulation. Thus, charming liposomes as a  transport that gives airplanes for drug management in AD (30).

L]  Advanced drug delivery systems (ADDS) for AD drugs: -

Despite the chance of healing drugs such as acetylcholinesterase inhibitors and NMDA receptor blockers for directing senility guide Alzheimer's disease, relapse on account of age progression and restricted transportation across the ancestry-intelligence barrier (BBB) remnants a challenge. While normal medicines like tablets and capsules exhibit important oral bioavailability, their efficiency decreases on account of determinants like first-pass metabolism, body tissue protein binding, and integral reactions. To address these challenges, various advanced drug transmittal orders (ADDS) containing lipid and polymer-located nanoparticles (NPs), gel-located structures, and drug-conjugates maybe employed. These childbirth bicycles have benefits over common delivery orders, place they can correct the pharmacokinetic limits (such as incorporation, allocation, absorption, and consent) of the drug, and can increase the solubility or permeation from organic membranes (BBB with the understanding of AD, PD etc). Also, these advance transmittal systems concede possibility raise toxicological or unfavourable backlashes via less uncovering of the drug to integral distribution. Whereas the use of particular ADD plan in any ailment endure expected legitimized in terms of biocompatibility and healing efficiency. Additionally, because diseases like Alzheimer's and Parkinson's demand lasting situation, reaching prolonged and maintained release of drugs is another approach to improve situation effectiveness. Pharmaceutical researcher’s general is energetically occupied on expanding ADDS formulations using miscellaneous methods and parts, achieving variable standards of boom. In the following divisions, AADS fabricated to transfer Memantine, Donepezil, Galantamine, and Rivastigmine to the intellect for the situation of AD will be considered, also the preclinical dossier these drugs are pictorial in composite fig.7  (48).                         

Fig7. Preclinical research documents written in last five age on advance childbirth plans of all the antagonistic-Alzheimer drugs (memantine, donepezil, rivastigmine and galantamine). The dossier is delivered in accordance with the delivery methods(48).

M] Advances in 3D models of neurodegeneration: -

The increase in the booklet of novel 3D models of neurodegeneration has create many arms of 3D models. These widely engage in four classifications: affecting animate nerve organs organoids, neurospheroids, stage-located models, and 3D bio printed models (49). In the article, most 3D models of neurodegeneration judge neurodegenerative study of plants through the vicinity of protein dysregulation (amyloid-β and tau for AD and α-synuclein for PD) (50). However, few models have dysfunction confirmed across diversified extents of neurodegenerative pathologies or distinguished accompanying in vivo dossier. We confer the traits of these arising 3D model types and check by means of what written models show the symbol pathologies of neurodegeneration: protein collection, oxidative stress, metabolic dysfunction, synaptic trimming, and raised invulnerable incitement (for a review on the pathologies of neurodegeneration, visualize (51). We more outline the benefits and troubles of each model and the suggestions of model variety, sophistication occasion, and throughput for assay rightness (fig8)(52).

Fig8. Neurodegenerative dysfunction in neural cell types (51).

CONCLUSION

Intranasal drug administration can bypass the blood-brain barrier and enable rapid, extensive distribution of medications within the brain, it presents a promising treatment option for Alzheimer's disease. By addressing key pathological features of Alzheimer's, such as tau proteins, Aβ amyloid proteins, and synaptic plaques, this strategy has demonstrated neuroprotective benefits. The comprehensive analysis highlights the potential of liposomes and nanoparticles as effective nasal drug delivery vehicles. Numerous advantages are offered by these advanced delivery systems, including increased drug stability, better targeting, and fewer systemic side effects. However, challenges still exist, such as limited dosage, rapid elimination, enzymatic degradation, and potential safety concerns. Despite these challenges, ongoing research and development projects seek to improve these delivery methods and resolve current constraints.

REFERENCES

        1. Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet [Internet]. 2016 Jul 30;388(10043):505–17. Available from: https://doi.org/10.1016/S0140-6736(15)01124-1
        2. Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol [Internet]. 2019 Jan 1;18(1):88–106. Available from: https://doi.org/10.1016/S1474-4422(18)30403-4
        3. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet [Internet]. 2020 Oct 17;396(10258):1204–22. Available from: https://doi.org/10.1016/S0140-6736(20)30925-9
        4. Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimer’s Dement. 2023;19(2):658–70.
        5. Srivastava S, Ahmad R, Khare SK. Alzheimer’s disease and its treatment by different approaches: A review. Eur J Med Chem [Internet]. 2021; 216:113320. Available from: https://www.sciencedirect.com/science/article/pii/S0223523421001690
        6. Bature F, Guinn B ann, Pang D, Pappas Y. Signs and symptoms preceding the diagnosis of Alzheimer’ s disease: a systematic scoping review of literature from 1937 to 2016. 2017;
        7. Pinyopornpanish K, Soontornpun A, Wongpakaran T. Impact of behavioral and psychological symptoms of Alzheimer’ s disease on caregiver outcomes. Sci Rep [Internet]. 2022;(0123456789):1–9. Available from: https://doi.org/10.1038/s41598-022-18470-8
        8. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020;25(24).
        9. James BD, Bennett DA. Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer’s Disease. Annu Rev Public Health. 2019; 40:65–84.
        10. Karantzoulis S, Galvin JE. Expert Review of Neurotherapeutics major forms of dementia Distinguishing Alzheimer’ s disease from other major forms of dementia. 2014;7175.
        11. McCubbrey AL, McManus SA, McClendon JD, Thomas SM, Chatwin HB, Reisz JA, et al. Polyamine import and accumulation causes immunomodulation in macrophages engulfing apoptotic cells. Cell Rep [Internet]. 2022;38(2):110222. Available from: https://doi.org/10.1016/j.celrep.2021.110222
        12. Tsering W, Prokop S. Neuritic Plaques — Gateways to Understanding Alzheimer’s Disease. Mol Neurobiol [Internet]. 2024;61(5):2808–21. Available from: https://doi.org/10.1007/s12035-023-03736-7
        13. 13.         Kidd PM. Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev. 2008 Jun;13(2):85–115.
        14. Taléns-Visconti R, de Julián-Ortiz JV, Vila-Busó O, Diez-Sales O, Nácher A. Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. Pharmaceutics. 2023 May;15(5).
        15. Myeong J, Kil B, Cho S jin, Suh Y hun. Stem Cell Therapy for Alzheimer’ s Disease: A Review of Recent Clinical Trials Development for The Treatment. 2016; 54:879–89.
        16. 16.         Patel D, Thakkar H. Formulation Considerations for Improving Intranasal Delivery of CNS Acting Therapeutics. Ther Deliv [Internet]. 2022 Jul 1;13(7):371–81. Available from: https://doi.org/10.4155/tde-2022-0018
        17. Kumar H, Mishra G, Sharma AK, Gothwal A, Kesharwani P, Gupta U. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics. Pharm Nanotechnol. 2017;5(3):203–14.
        18. Bahadur S, Jha MK. Emerging nanoformulations for drug targeting to brain through intranasal delivery: A comprehensive review. J Drug Deliv Sci Technol [Internet]. 2022; 78:103932. Available from: https://www.sciencedirect.com/science/article/pii/S1773224722008437
        19. Marcello E, Chiono V. Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting. Int J Mol Sci. 2023 Feb;24(4).
        20. Govender M, Indermun S, Kumar P, Choonara Y. Potential Targeting Sites to the Brain Through Nasal Passage. In 2023. p. 83–99.
        21. Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Control release Off J Control Release Soc. 2017 Dec; 268:364–89.
        22. Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig [Internet]. 2023;53(1):119–52. Available from: https://doi.org/10.1007/s40005-022-00589-5
        23. Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today [Internet]. 2022;29(August):101631. Available from: https://doi.org/10.1016/j.apmt.2022.101631
        24. Chen Y, Zhang C, Huang Y, Ma Y, Song Q, Chen H, et al. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. Adv Drug Deliv Rev [Internet]. 2024; 207:115196. Available from: https://www.sciencedirect.com/science/article/pii/S0169409X24000188
        25. Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol [Internet]. 2021; 167:382–94. Available from: https://www.sciencedirect.com/science/article/pii/S0141813020351308
        26. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP, et al. Expression of APP pathway mRNAs and proteins in Alzheimer’s disease. Brain Res [Internet]. 2007; 1161:116–23. Available from: https://www.sciencedirect.com/science/article/pii/S0006899307012644
        27. Tackenberg C, Nitsch RM. The secreted APP ectodomain sAPPα, but not sAPPβ, protects neurons against Aβ oligomer-induced dendritic spine loss and increased tau phosphorylation. Mol Brain. 2019;12(1):10–3.
        28. Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol Sin [Internet]. 2017;38(9):1205–35. Available from: http://dx.doi.org/10.1038/aps.2017.28
        29. Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH. Amyloid Beta in Aging and Alzheimer’s Disease. Int J Mol Sci. 2022;23(21).
        30. Patel RJ, Patel AA, Trivedi N, Pandya V, Alexander A, Patel V, et al. Chapter 10 - Liposomes as carrier for drug delivery in Alzheimer’s disease. In: Prajapati BG, Chellappan DK, Kendre PN, editors. Alzheimer’s Disease and Advanced Drug Delivery Strategies [Internet]. Academic Press; 2024. p. 153–79. Available from: https://www.sciencedirect.com/science/article/pii/B978044313205600008X
        31. Wen MM, El-Salamouni NS, El-Refaie WM, Hazzah HA, Ali MM, Tosi G, et al. Nanotechnology-based drug delivery systems for Alzheimer’s disease management:  Technical, industrial, and clinical challenges. J Control release Off J Control Release Soc. 2017 Jan; 245:95–107.
        32. Chigurupati S, Mughal MR, Okun E, Das S, Kumar A, McCaffery M, et al. Effects of cerium oxide nanoparticles on the growth of keratinocytes, fibroblasts and vascular endothelial cells in cutaneous wound healing. Biomaterials. 2013 Mar;34(9):2194–201.
        33. Kim CK, Kim T, Choi IY, Soh M, Kim D, Kim YJ, et al. Ceria nanoparticles that can protect against ischemic stroke. Angew Chem Int Ed Engl. 2012 Oct;51(44):11039–43.
        34. Yin T, Yang L, Liu Y, Zhou X, Sun J, Liu J. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood–brain barrier permeability peptide-B6 peptide for potential use in Alzheimer’s disease. Acta Biomater [Internet]. 2015; 25:172–83. Available from: https://www.sciencedirect.com/science/article/pii/S1742706115300076
        35. Kwon HJ, Cha MY, Kim D, Kim DK, Soh M, Shin K, et al. Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease. ACS Nano. 2016 Feb;10(2):2860–70.
        36. Weekley CM, Harris HH. Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease. Chem Soc Rev. 2013 Dec;42(23):8870–94.
        37. Balaban H, Naz?ro?lu M, Demirci K, Övey ?S. The Protective Role of Selenium on Scopolamine-Induced Memory Impairment, Oxidative Stress, and Apoptosis in Aged Rats: The Involvement of TRPM2 and TRPV1 Channels. Mol Neurobiol [Internet]. 2017;54(4):2852–68. Available from: https://doi.org/10.1007/s12035-016-9835-0
        38. Prajapati V, Shinde S, Shrivastav P, Prajapati BG. Chapter 7 - New biologicals and biomaterials in the therapy of Alzheimer’s disease. In: Prajapati BG, Chellappan DK, Kendre PN, editors. Alzheimer’s Disease and Advanced Drug Delivery Strategies [Internet]. Academic Press; 2024. p. 93–114. Available from: https://www.sciencedirect.com/science/article/pii/B9780443132056000169
        39. Gizurarson S. Animal models for intranasal drug delivery studies. A review articles. Acta Pharm Nord [Internet]. 1990;2(2):105—122. Available from: http://europepmc.org/abstract/MED/2191690
        40. Dimova S, Brewster ME, Noppe M, Jorissen M, Augustijns P. The use of human nasal in vitro cell systems during drug discovery and development. Toxicol Vitr [Internet]. 2005;19(1):107–22. Available from: https://www.sciencedirect.com/science/article/pii/S0887233304001237
        41. Esim O, Savaser A, Ozkan CK, Oztuna A, Goksel BA, Ozler M, et al. Nose to brain delivery of eletriptan hydrobromide nanoparticles: Preparation, in vitro/in vivo evaluation and effect on trigeminal activation. J Drug Deliv Sci Technol [Internet]. 2020; 59:101919. Available from: https://www.sciencedirect.com/science/article/pii/S1773224720312089
        42. Yasir M, Chauhan I, Zafar A, Verma M, Noorulla KM, Tura AJ, et al. Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: Formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation. J Drug Deliv Sci Technol [Internet]. 2021; 61:102164. Available from: https://www.sciencedirect.com/science/article/pii/S1773224720314532
        43. Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol [Internet]. 2018; 109:27–35. Available from: https://www.sciencedirect.com/science/article/pii/S0141813017336978
        44. Silva S, Bicker J, Fonseca C, Ferreira NR, Vitorino C, Alves G, et al. Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation. Front Pharmacol. 2021;12(December).
        45. Qureshi M, Aqil M, Imam SS, Ahad A, Sultana Y. Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study. Curr Drug Deliv. 2019;16(2):123–35.
        46. Boyuklieva R, Zagorchev P, Pilicheva B. Computational, In Vitro, and In Vivo Models for Nose-to-Brain Drug Delivery Studies. Biomedicines. 2023;11(8).
        47. Singh B, Day CM, Abdella S, Garg S. Alzheimer’s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release [Internet]. 2024;367(January):402–24. Available from: https://doi.org/10.1016/j.jconrel.2024.01.047
        48. Slanzi A, Iannoto G, Rossi B, Zenaro E, Constantin G. In vitro Models of Neurodegenerative Diseases. Front Cell Dev Biol. 2020;8(May).
        49. Jorfi M, D’Avanzo C, Tanzi RE, Kim DY, Irimia D. Human Neurospheroid Arrays for In Vitro Studies of Alzheimer’s Disease. Sci Rep [Internet]. 2018;8(1):2450. Available from: https://doi.org/10.1038/s41598-018-20436-8
        50. Tesco G, Lomoio S. Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation? Semin Immunol. 2022 Jan; 59:101628.
        51. Whitehouse C, Corbett N, Brownlees J. 3D models of neurodegeneration: implementation in drug discovery. Trends Pharmacol Sci. 2023 Apr;44(4):208–21.

Reference

  1. Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet [Internet]. 2016 Jul 30;388(10043):505–17. Available from: https://doi.org/10.1016/S0140-6736(15)01124-1
  2. Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol [Internet]. 2019 Jan 1;18(1):88–106. Available from: https://doi.org/10.1016/S1474-4422(18)30403-4
  3. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet [Internet]. 2020 Oct 17;396(10258):1204–22. Available from: https://doi.org/10.1016/S0140-6736(20)30925-9
  4. Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimer’s Dement. 2023;19(2):658–70.
  5. Srivastava S, Ahmad R, Khare SK. Alzheimer’s disease and its treatment by different approaches: A review. Eur J Med Chem [Internet]. 2021; 216:113320. Available from: https://www.sciencedirect.com/science/article/pii/S0223523421001690
  6. Bature F, Guinn B ann, Pang D, Pappas Y. Signs and symptoms preceding the diagnosis of Alzheimer’ s disease: a systematic scoping review of literature from 1937 to 2016. 2017;
  7. Pinyopornpanish K, Soontornpun A, Wongpakaran T. Impact of behavioral and psychological symptoms of Alzheimer’ s disease on caregiver outcomes. Sci Rep [Internet]. 2022;(0123456789):1–9. Available from: https://doi.org/10.1038/s41598-022-18470-8
  8. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020;25(24).
  9. James BD, Bennett DA. Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer’s Disease. Annu Rev Public Health. 2019; 40:65–84.
  10. Karantzoulis S, Galvin JE. Expert Review of Neurotherapeutics major forms of dementia Distinguishing Alzheimer’ s disease from other major forms of dementia. 2014;7175.
  11. McCubbrey AL, McManus SA, McClendon JD, Thomas SM, Chatwin HB, Reisz JA, et al. Polyamine import and accumulation causes immunomodulation in macrophages engulfing apoptotic cells. Cell Rep [Internet]. 2022;38(2):110222. Available from: https://doi.org/10.1016/j.celrep.2021.110222
  12. Tsering W, Prokop S. Neuritic Plaques — Gateways to Understanding Alzheimer’s Disease. Mol Neurobiol [Internet]. 2024;61(5):2808–21. Available from: https://doi.org/10.1007/s12035-023-03736-7
  13. 13.         Kidd PM. Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev. 2008 Jun;13(2):85–115.
  14. Taléns-Visconti R, de Julián-Ortiz JV, Vila-Busó O, Diez-Sales O, Nácher A. Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. Pharmaceutics. 2023 May;15(5).
  15. Myeong J, Kil B, Cho S jin, Suh Y hun. Stem Cell Therapy for Alzheimer’ s Disease: A Review of Recent Clinical Trials Development for The Treatment. 2016; 54:879–89.
  16. 16.         Patel D, Thakkar H. Formulation Considerations for Improving Intranasal Delivery of CNS Acting Therapeutics. Ther Deliv [Internet]. 2022 Jul 1;13(7):371–81. Available from: https://doi.org/10.4155/tde-2022-0018
  17. Kumar H, Mishra G, Sharma AK, Gothwal A, Kesharwani P, Gupta U. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics. Pharm Nanotechnol. 2017;5(3):203–14.
  18. Bahadur S, Jha MK. Emerging nanoformulations for drug targeting to brain through intranasal delivery: A comprehensive review. J Drug Deliv Sci Technol [Internet]. 2022; 78:103932. Available from: https://www.sciencedirect.com/science/article/pii/S1773224722008437
  19. Marcello E, Chiono V. Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting. Int J Mol Sci. 2023 Feb;24(4).
  20. Govender M, Indermun S, Kumar P, Choonara Y. Potential Targeting Sites to the Brain Through Nasal Passage. In 2023. p. 83–99.
  21. Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Control release Off J Control Release Soc. 2017 Dec; 268:364–89.
  22. Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig [Internet]. 2023;53(1):119–52. Available from: https://doi.org/10.1007/s40005-022-00589-5
  23. Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today [Internet]. 2022;29(August):101631. Available from: https://doi.org/10.1016/j.apmt.2022.101631
  24. Chen Y, Zhang C, Huang Y, Ma Y, Song Q, Chen H, et al. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. Adv Drug Deliv Rev [Internet]. 2024; 207:115196. Available from: https://www.sciencedirect.com/science/article/pii/S0169409X24000188
  25. Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol [Internet]. 2021; 167:382–94. Available from: https://www.sciencedirect.com/science/article/pii/S0141813020351308
  26. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP, et al. Expression of APP pathway mRNAs and proteins in Alzheimer’s disease. Brain Res [Internet]. 2007; 1161:116–23. Available from: https://www.sciencedirect.com/science/article/pii/S0006899307012644
  27. Tackenberg C, Nitsch RM. The secreted APP ectodomain sAPPα, but not sAPPβ, protects neurons against Aβ oligomer-induced dendritic spine loss and increased tau phosphorylation. Mol Brain. 2019;12(1):10–3.
  28. Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol Sin [Internet]. 2017;38(9):1205–35. Available from: http://dx.doi.org/10.1038/aps.2017.28
  29. Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH. Amyloid Beta in Aging and Alzheimer’s Disease. Int J Mol Sci. 2022;23(21).
  30. Patel RJ, Patel AA, Trivedi N, Pandya V, Alexander A, Patel V, et al. Chapter 10 - Liposomes as carrier for drug delivery in Alzheimer’s disease. In: Prajapati BG, Chellappan DK, Kendre PN, editors. Alzheimer’s Disease and Advanced Drug Delivery Strategies [Internet]. Academic Press; 2024. p. 153–79. Available from: https://www.sciencedirect.com/science/article/pii/B978044313205600008X
  31. Wen MM, El-Salamouni NS, El-Refaie WM, Hazzah HA, Ali MM, Tosi G, et al. Nanotechnology-based drug delivery systems for Alzheimer’s disease management:  Technical, industrial, and clinical challenges. J Control release Off J Control Release Soc. 2017 Jan; 245:95–107.
  32. Chigurupati S, Mughal MR, Okun E, Das S, Kumar A, McCaffery M, et al. Effects of cerium oxide nanoparticles on the growth of keratinocytes, fibroblasts and vascular endothelial cells in cutaneous wound healing. Biomaterials. 2013 Mar;34(9):2194–201.
  33. Kim CK, Kim T, Choi IY, Soh M, Kim D, Kim YJ, et al. Ceria nanoparticles that can protect against ischemic stroke. Angew Chem Int Ed Engl. 2012 Oct;51(44):11039–43.
  34. Yin T, Yang L, Liu Y, Zhou X, Sun J, Liu J. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood–brain barrier permeability peptide-B6 peptide for potential use in Alzheimer’s disease. Acta Biomater [Internet]. 2015; 25:172–83. Available from: https://www.sciencedirect.com/science/article/pii/S1742706115300076
  35. Kwon HJ, Cha MY, Kim D, Kim DK, Soh M, Shin K, et al. Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease. ACS Nano. 2016 Feb;10(2):2860–70.
  36. Weekley CM, Harris HH. Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease. Chem Soc Rev. 2013 Dec;42(23):8870–94.
  37. Balaban H, Naz?ro?lu M, Demirci K, Övey ?S. The Protective Role of Selenium on Scopolamine-Induced Memory Impairment, Oxidative Stress, and Apoptosis in Aged Rats: The Involvement of TRPM2 and TRPV1 Channels. Mol Neurobiol [Internet]. 2017;54(4):2852–68. Available from: https://doi.org/10.1007/s12035-016-9835-0
  38. Prajapati V, Shinde S, Shrivastav P, Prajapati BG. Chapter 7 - New biologicals and biomaterials in the therapy of Alzheimer’s disease. In: Prajapati BG, Chellappan DK, Kendre PN, editors. Alzheimer’s Disease and Advanced Drug Delivery Strategies [Internet]. Academic Press; 2024. p. 93–114. Available from: https://www.sciencedirect.com/science/article/pii/B9780443132056000169
  39. Gizurarson S. Animal models for intranasal drug delivery studies. A review articles. Acta Pharm Nord [Internet]. 1990;2(2):105—122. Available from: http://europepmc.org/abstract/MED/2191690
  40. Dimova S, Brewster ME, Noppe M, Jorissen M, Augustijns P. The use of human nasal in vitro cell systems during drug discovery and development. Toxicol Vitr [Internet]. 2005;19(1):107–22. Available from: https://www.sciencedirect.com/science/article/pii/S0887233304001237
  41. Esim O, Savaser A, Ozkan CK, Oztuna A, Goksel BA, Ozler M, et al. Nose to brain delivery of eletriptan hydrobromide nanoparticles: Preparation, in vitro/in vivo evaluation and effect on trigeminal activation. J Drug Deliv Sci Technol [Internet]. 2020; 59:101919. Available from: https://www.sciencedirect.com/science/article/pii/S1773224720312089
  42. Yasir M, Chauhan I, Zafar A, Verma M, Noorulla KM, Tura AJ, et al. Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: Formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation. J Drug Deliv Sci Technol [Internet]. 2021; 61:102164. Available from: https://www.sciencedirect.com/science/article/pii/S1773224720314532
  43. Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol [Internet]. 2018; 109:27–35. Available from: https://www.sciencedirect.com/science/article/pii/S0141813017336978
  44. Silva S, Bicker J, Fonseca C, Ferreira NR, Vitorino C, Alves G, et al. Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation. Front Pharmacol. 2021;12(December).
  45. Qureshi M, Aqil M, Imam SS, Ahad A, Sultana Y. Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study. Curr Drug Deliv. 2019;16(2):123–35.
  46. Boyuklieva R, Zagorchev P, Pilicheva B. Computational, In Vitro, and In Vivo Models for Nose-to-Brain Drug Delivery Studies. Biomedicines. 2023;11(8).
  47. Singh B, Day CM, Abdella S, Garg S. Alzheimer’s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release [Internet]. 2024;367(January):402–24. Available from: https://doi.org/10.1016/j.jconrel.2024.01.047
  48. Slanzi A, Iannoto G, Rossi B, Zenaro E, Constantin G. In vitro Models of Neurodegenerative Diseases. Front Cell Dev Biol. 2020;8(May).
  49. Jorfi M, D’Avanzo C, Tanzi RE, Kim DY, Irimia D. Human Neurospheroid Arrays for In Vitro Studies of Alzheimer’s Disease. Sci Rep [Internet]. 2018;8(1):2450. Available from: https://doi.org/10.1038/s41598-018-20436-8
  50. Tesco G, Lomoio S. Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation? Semin Immunol. 2022 Jan; 59:101628.
  51. Whitehouse C, Corbett N, Brownlees J. 3D models of neurodegeneration: implementation in drug discovery. Trends Pharmacol Sci. 2023 Apr;44(4):208–21.

Photo
Kirti Dewaikar
Corresponding author

Department of Pharmacology, Kamla Nehru College of Pharmacy, Butibori, Nagpur, Maharashtra, India

Photo
Dr. Jagdish Baheti
Co-author

Department of Pharmacology, Kamla Nehru College of Pharmacy, Butibori, Nagpur, Maharashtra, India

Photo
Shilpa Borkar
Co-author

Department of Pharmacology, Kamla Nehru College of Pharmacy, Butibori, Nagpur, Maharashtra, India

Dr. Jagdish Baheti, Shilpa Borkar, Kirti Dewaikar*, Review Paper on Intranasal Drug Delivery System for Alzheimer’s Cognition, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 7, 271-285. https://doi.org/10.5281/zenodo.15789689

More related articles
Analytical Techniques for Quantification of Iohexo...
Vaibhavi Meshram, Alpana Asnani, Pooja Wankhade, Vaishnavi Nikhad...
Matrix-Based Sustained Release Formulations of Met...
Dhage Shubhangi , Lonkar Sagar , Naik Pranav , Khaladkar Shraddha...
Biochemical Mechanism of Healing Activity of the N...
Kirti Pawar, Dipali Suryawanshi, Dhiraj Patil, ...
An Overview on Artificial Blood...
Rajnandini Ahire, Mukesh Ratnaparkhi, Shital Kshirsagar, Devang Mahale, ...
An Interventional Study On Hemodialysis Patient And Impact Of Patient Counseling...
Basheera. V, Rahna Rasheed, Remeeza Jabbar, Rinsa. A, ...
Enhanced Acne Treatment Efficacy: The Role of Personalized Nanogel Formulation ...
Sara Rai , Beny Baby, S. Rajarajan , Survi Barnawal, ...
Related Articles
Review on 'Polycystic kidney disease pathophysiology and prognosis'...
Seema Kashyap, Eshu Sahu, Bignesh Pradhan, Dali Kanwar, Chhabi Lal, ...
Benzocaine Topical Spray: A Local Anesthetic For Pain Management ...
Sharayu Kumbhar , Radhika Subhedar, Nilesh B. Chougule, ...
Preparation And Evaluation Of Herbal Hair Spray...
Nikunj Patadiya, Hetal Dalvi , Priti Patel , Darshana Dalvi , Shilpa Patel , ...
A Detailed Review on Pharmaceutical Applications of Pickering Emulsion...
Neha Joshy, Vinu Gopakumar Krishna , Prasanth M. S., ...
Analytical Techniques for Quantification of Iohexol in Pharmaceutical Preparatio...
Vaibhavi Meshram, Alpana Asnani, Pooja Wankhade, Vaishnavi Nikhade, Madhuri Fating, Nikita Gaikwad, ...
More related articles
Analytical Techniques for Quantification of Iohexol in Pharmaceutical Preparatio...
Vaibhavi Meshram, Alpana Asnani, Pooja Wankhade, Vaishnavi Nikhade, Madhuri Fating, Nikita Gaikwad, ...
Matrix-Based Sustained Release Formulations of Metformin Hydrochloride: Current ...
Dhage Shubhangi , Lonkar Sagar , Naik Pranav , Khaladkar Shraddha, ...
Analytical Techniques for Quantification of Iohexol in Pharmaceutical Preparatio...
Vaibhavi Meshram, Alpana Asnani, Pooja Wankhade, Vaishnavi Nikhade, Madhuri Fating, Nikita Gaikwad, ...
Matrix-Based Sustained Release Formulations of Metformin Hydrochloride: Current ...
Dhage Shubhangi , Lonkar Sagar , Naik Pranav , Khaladkar Shraddha, ...